

PATENT  
1151-4158US1  
U.S.S.N. 09/701,588

- A4
14. A peptide immunogen according to Claim 13 selected from the group consisting of SEQ ID NOs:148 - 150, and 151.

A marked-up version of the amended claims is in the Appendix attached hereto.

REMARKS

Claims 1, 2, 9, 11, 13 and 14 have been amended to recite the Markush group in proper language. Support for the amendment is found in originally filed Claims 1, 2 9, 11, 13 and 14. No new matter is presented. Entry of the amendment is requested.

RESPONSE


Claims 1, 2, 9, 11, 13 and 14 were rejected as indefinite by the Examiner for using Markush group language that is incorrect in claim 1, line 2, claim 2, line 20, claims 9, 11, 13 and 14, line 2. Claims 1, 2, 9, 11, 13 and 14 have been amended to correctly recite the Markush groups. Reconsideration of the rejection is requested.

As amended the claims employ correct Markush language and the rejection on this ground has been overcome and is now moot. It is clear that the amendment does not narrow the scope of the invention originally claimed.

The Examiner indicated that the claims distinguish over prior art and are allowable if amended.

Claims 3-8, 10, 12 and 15-33 have been allowed. It is believed that as amended claims 1, 2, 9, 11, 13 and 14 are allowable and an early allowance is requested.

Respectfully submitted,

  
Maria C.H. Lin

Registration No. 29,323

Date: January 18, 2002

Morgan & Finnegan, L.L.P.  
345 Park Avenue  
New York, New York 10154  
Tel. No. (212) 758-4800  
Fax. No. (212) 751-6849  
Direct Line: (212) 415-0745